Home › Trial NCT04126876
A Randomized Controlled Phase II Trial With Intradermal IMO-2125 in Pathological Tumor Stage (p) T3-4 cN0M0 Melanoma
- Trial IDNCT04126876
- StatusRecruiting
- PhasePhase 2
- Study typeInterventional
- SponsorA.J.M. van den Eertwegh
- Enrollment214
- Start date2020-01-22
- ConditionsMalignant Melanoma
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.